… Heng et al … Heng et al … Golshayan AR, George S, Heng DY, et al: Metastatic
sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor–targeted …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …

Background The International Metastatic Renal-Cell Carcinoma Database Consortium model
offers prognostic information for patients with metastatic renal-cell carcinoma. We tested …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …

Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed
superior efficacy over sunitinib in patients with previously untreated intermediate-risk or …

Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …

Purpose Combination treatment with immune checkpoint inhibitors has shown enhanced
antitumor activity compared with monotherapy in tumor types such as melanoma. The open-…

Purpose : Vascular endothelial growth factor targeted therapy is a standard of care in patients
with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of …

Background Previous prognostic models for second-line systemic therapy in patients with
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …